Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
May 01 2024 - 6:05AM
Business Wire
Data to be presented will highlight latest
preclinical safety data for PBGENE-HBV in preparation for
regulatory filings in 2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene elimination, insertion, and excision, today
announced that the company will present late-breaking preclinical
data from its clinical candidate, PBGENE-HBV, for the treatment of
chronic hepatitis B (HBV) during a poster presentation at the
European Association for Study of the Liver (EASL) Congress 2024
being held June 5-8, 2024 in Milan, Italy.
“We look forward to the opportunity to share the latest new
preclinical safety data from our PBGENE-HBV clinical candidate at
the EASL Congress,” said Jeff Smith, Co-Founder and Chief Research
Officer at Precision BioSciences. “The late-breaking safety data to
be presented at EASL, combined with our recent pre-IND feedback
from both U.S. and international Regulators, adds to the body of
evidence supporting continued progression of PBGENE-HBV as we
pursue the goal to be the first potentially curative gene editing
program to enter the clinic for HBV. PBGENE-HBV is designed to
safely eliminate cccDNA and inactivate integrated HBV DNA. As we
look ahead, we remain on track to file an investigational new drug
(IND) and/or clinical trial application (CTA) in 2024.”
Presentation Details:
Title: Preclinical safety data for PBGENE-HBV gene
editing program supports advancement to clinical trials as a
potentially curative treatment for chronic hepatitis B Abstract
Number: LB195 Presenter: Emily Harrison, Senior
Scientist - Hepatitis Research Leader, Precision Biosciences
Date and Time: Wednesday, June 5, 2024, 8:30 AM – Saturday,
June 8, 2024, 5:00 PM CEST
About Hepatitis B and PBGENE-HBV:
Hepatitis B is a leading cause of morbidity in the US and death
globally, with no curative options currently available for
patients. In 2019, despite the availability of approved antiviral
therapies, an estimated 300 million people globally and more than 1
million people in the US were estimated to have chronic hepatitis B
infection. An estimated 15% to 40% of patients with HBV infections
may develop complications, such as cirrhosis, liver failure, or
liver cancer (hepatocellular carcinoma), which account for the
majority of HBV-related deaths.
Chronic hepatitis B infection is primarily driven by persistence
of HBV cccDNA and integration of HBV DNA into the human genome in
liver cells, the primary source of HBsAg in late-stage disease.
Current treatments for patients with HBV infection include agents
that result in long-term viral suppression as indicated by
reduction of circulating HBV DNA, but these therapies do not
eradicate HBV cccDNA, rarely lead to functional cure, and require
lifelong administration. PBGENE-HBV is a highly specific, novel
therapeutic approach to treating patients with chronic HBV
infection. It’s designed to directly eliminate cccDNA and
inactivate integrated HBV DNA with high specificity, potentially
leading to functional cures.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene
editing therapies for sophisticated gene edits, including gene
insertion (inserting DNA into gene to cause expression/add
function), elimination (removing a genome e.g. viral DNA or mutant
mitochondrial DNA), and excision (removing a large portion of a
defective gene by delivering two ARCUS nucleases in a single
AAV).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501949627/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Apr 2024 to May 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From May 2023 to May 2024